Loading...
XNAS
ICPT
Market cap1.28bUSD
Nov 07, Last price  
19.00USD
Name

Intercept Pharmaceuticals Inc

Chart & Performance

D1W1MN
No data to show
P/E
6.90
P/S
2.78
EPS
2.75
Div Yield, %
—
Shrs. gr., 5y
6.19%
Rev. gr., 5y
16.89%
Revenues
286m
-21.39%
01,805,1302,446,0001,621,6271,742,0002,782,00024,951,000130,956,000179,804,000252,002,000312,690,000363,468,000285,710,000
Net income
115m
P
-15,087,223-12,737,654-43,644,000-67,792,410-283,226,000-226,429,000-412,830,000-360,367,000-309,242,000-391,052,000-324,230,000-145,022,000115,174,000
CFO
-27m
L-35.69%
-13,657,8232,605,786-15,749,468-28,006,409-87,738,344-162,902,000-342,441,000-265,402,000-240,714,000-236,613,000-170,026,000-41,639,000-26,780,000

Profile

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
URL
https://www.interceptpharma.com/
IPO date
Oct 11, 2012
Employees
341
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
285,710
-21.39%
Cost of revenue
177,623
Unusual Expense (Income)
NOPBT
108,087
NOPBT Margin
37.83%
Operating Taxes
(290,032)
Tax Rate
NOPAT
398,119
Net income
115,174
-179.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
(557)
BB yield
0.13%
Debt
Debt current
109,569
Long-term debt
223,104
Deferred revenue
Other long-term liabilities
7,453
Net debt
(158,236)
Cash flow
Cash from operating activities
(26,780)
CAPEX
(568)
Cash from investing activities
261,849
Cash from financing activities
(267,316)
FCF
406,628
Balance
Cash
490,909
Long term investments
Excess cash
476,624
Stockholders' equity
(2,145,102)
Invested Capital
2,575,161
ROIC
14.66%
ROCE
25.13%
EV
Common stock shares outstanding
33,837
Price
12.37
-24.06%
Market cap
418,564
-19.44%
EV
260,328
EBITDA
108,679
EV/EBITDA
2.40
Interest
21,385
Interest/NOPBT
19.78%